1,028 results on '"Caplin, Martyn"'
Search Results
2. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
3. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
4. Endoscopic submucosal dissection for rectal neuroendocrine tumours: A multicentric retrospective study
5. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
6. Where Are We Now with Liver Transplantation in Neuroendocrine Neoplasms? The Place of Liver Transplantation for Grades 1 and 2 Well-Differentiated Unresectable Liver Metastatic Neuroendocrine Tumours
7. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
8. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome
9. What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?
10. Safety and Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease
11. Long‐Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome
12. Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study
13. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours.
14. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
15. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
16. Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
17. 177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life
18. Features of carcinoid heart disease identified by cardiac computed tomography
19. Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms : A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.
20. [18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
21. Management of patients with rare adult solid cancers:objectives and evaluation of European reference networks (ERN) EURACAN
22. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.
23. The Clinical Utility of the NETest in Patients with Small Intestinal Neuroendocrine Neoplasms (Si-NENs): A "Real-Life" Study.
24. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
25. Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
26. Endoscopic Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours: An Overview of Proposed Resection and Ablation Techniques
27. Carcinoid Syndrome
28. Gastrinoma
29. [18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
30. Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection
31. Clinicopathological correlations of mesenteric fibrosis and evaluation of a novel biomarker for fibrosis detection in small bowel neuroendocrine neoplasms
32. Orbital metastases from neuroendocrine neoplasms: clinical implications and outcomes
33. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
34. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact
35. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours
36. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours
37. Management Strategies and Outcomes for Small Intestinal Neuroendocrine Tumours with Involvement of the Superior Mesenteric Vessels: A Systematic Review
38. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
39. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours
40. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
41. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
42. Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.
43. Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours.
44. The role of gastrin and CCK-B/gastrin receptor in hepatocellular and pancreatic cancers
45. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
46. The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas
47. Diagnostic and therapeutic advances in neuroendocrine tumours
48. 177Lu DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in advanced Phaeochromocytomas and paragangliomas (PPGL) - a single centre experience at a ENETS Centre of Excellence
49. Supplementary Figure from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
50. Data from Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.